Biomarkers in lymphedema assessment: integrating elastography and muti-frequency bioimpedance analysis.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2024-10-24 DOI:10.1080/17520363.2024.2415283

Hyeonwoo Jeon, Doo Young Kim, Si-Woon Park, Bum-Suk Lee, Daham Kim, Hyeong-Wook Han, Namo Jeon

{"title":"Biomarkers in lymphedema assessment: integrating elastography and muti-frequency bioimpedance analysis.","authors":"Hyeonwoo Jeon, Doo Young Kim, Si-Woon Park, Bum-Suk Lee, Daham Kim, Hyeong-Wook Han, Namo Jeon","doi":"10.1080/17520363.2024.2415283","DOIUrl":null,"url":null,"abstract":"Aim: Multi-frequency bioimpedance analysis (MFBIA) is used to measure lymphedema, but it is a biomarker that is sensitive to stiffness. Lymphedema is a condition that can be accompanied by stiffness, but no studies have considered this, so we tried to use non-invasive elastography as a biomarker for stiffness.Methods & results: This retrospective study included 102 patients with lymphedema, divided into two groups according to the elastography strain ratio: stiff group (elastography strain ratio <0.7, n = 48) and non-stiff group (elastography strain ratio >0.7, n = 54). We estimated the volume of the affected arm based the extracellular water (ECW) volume calculated using MFBIA through a simple linear regression method. The adjusted R2 was 0.044 in the stiff group and 0.729 in the non-stiff group. Stepwise multivariate linear regression was used to investigate the significant factors for estimating the affected arm volume for each group. In the non-stiff group, the significantly associated factors were impedance at 50 kHz, weight, and height (adjusted R2 = 0.724; p = 0.003). In the stiff group, significant associations were observed among impedance at 250 kHz, impedance at 1 kHz, weight, and height (adjusted R2 = 0.705, p = 0.041).Conclusion: Considering the characteristics of lymphedema, using MFBIA concurrently with elastography can be useful biomarker for estimating lymphedema.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-11"},"PeriodicalIF":1.9000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2024.2415283","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Multi-frequency bioimpedance analysis (MFBIA) is used to measure lymphedema, but it is a biomarker that is sensitive to stiffness. Lymphedema is a condition that can be accompanied by stiffness, but no studies have considered this, so we tried to use non-invasive elastography as a biomarker for stiffness.Methods & results: This retrospective study included 102 patients with lymphedema, divided into two groups according to the elastography strain ratio: stiff group (elastography strain ratio <0.7, n = 48) and non-stiff group (elastography strain ratio >0.7, n = 54). We estimated the volume of the affected arm based the extracellular water (ECW) volume calculated using MFBIA through a simple linear regression method. The adjusted R2 was 0.044 in the stiff group and 0.729 in the non-stiff group. Stepwise multivariate linear regression was used to investigate the significant factors for estimating the affected arm volume for each group. In the non-stiff group, the significantly associated factors were impedance at 50 kHz, weight, and height (adjusted R² = 0.724; p = 0.003). In the stiff group, significant associations were observed among impedance at 250 kHz, impedance at 1 kHz, weight, and height (adjusted R² = 0.705, p = 0.041).Conclusion: Considering the characteristics of lymphedema, using MFBIA concurrently with elastography can be useful biomarker for estimating lymphedema.

查看原文本刊更多论文

淋巴水肿评估中的生物标志物：弹性成像和多频生物阻抗分析的整合。

目的：多频生物阻抗分析（MFBIA）用于测量淋巴水肿，但它是一种对僵硬度敏感的生物标志物。淋巴水肿是一种可能伴有僵硬的疾病，但没有研究考虑到这一点，因此我们尝试使用无创弹性成像技术作为僵硬度的生物标志物：这项回顾性研究包括102名淋巴水肿患者，根据弹性成像应变比分为两组：僵硬组（弹性成像应变比为0.7，n = 54）。我们根据使用 MFBIA 计算出的细胞外水（ECW）体积，通过简单的线性回归方法估算出患臂的体积。僵硬组的调整 R2 为 0.044，非僵硬组为 0.729。采用逐步多元线性回归法研究了估算各组患臂体积的重要因素。在非僵硬组中，50 kHz 时的阻抗、体重和身高（调整后的 R2 = 0.724；p = 0.003）是重要的相关因素。在僵硬组，250 kHz 时的阻抗、1 kHz 时的阻抗、体重和身高（调整后的 R2 = 0.705，p = 0.041）之间存在明显关联：考虑到淋巴水肿的特点，同时使用MFBIA和弹性成像可作为估测淋巴水肿的有用生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.